Literature DB >> 30143834

Haloperidol serum concentrations in critically ill patients included in the REDUCE study.

Anne W van Schijndel1, Eric J F Franssen2, Peter Pickkers3, Saskia Rijkenberg1, Mark van den Boogaard3, Peter H J van der Voort4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30143834     DOI： 10.1007/s00134-018-5348-9

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  1 in total

1.  Effect of Haloperidol on Survival Among Critically Ill Adults With a High Risk of Delirium: The REDUCE Randomized Clinical Trial.

Authors:  Mark van den Boogaard; Arjen J C Slooter; Roger J M Brüggemann; Lisette Schoonhoven; Albertus Beishuizen; J Wytze Vermeijden; Danie Pretorius; Jan de Koning; Koen S Simons; Paul J W Dennesen; Peter H J Van der Voort; Saskia Houterman; J G van der Hoeven; Peter Pickkers; Anna Besselink; Lieuwe S Hofstra; Peter E Spronk; Walter van den Bergh; Dirk W Donker; Malaika Fuchs; Attila Karakus; M Koeman; Mirella van Duijnhoven; Gerjon Hannink
Journal:  JAMA       Date:  2018-02-20       Impact factor: 56.272
  1 in total
  1 in total

1.  Focus on delirium, sedation and neuro critical care 2019: towards a more brain-friendly environment?

Authors:  Geert Meyfroidt; Martin Smith
Journal:  Intensive Care Med       Date:  2019-07-24       Impact factor: 17.440
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.